Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Tracking Resistance to Artemisinin Collaboration II (TRACII) study has begun recruitment, with about 180 subjects enrolled to date in 12 sites in seven countries in Asia and Africa, researchers announced at the second TRACII investigators’ meeting held 7 March in Bangkok.

Researcher looking down a microscope

17 March 2016, Bangkok – The Tracking Resistance to Artemisinin Collaboration II (TRACII) study has begun recruitment, with about 180 subjects enrolled to date in 12 sites in seven countries in Asia and Africa, researchers announced at the second TRACII investigators’ meeting held 7 March in Bangkok.

In 2014, the first TRAC study confirmed that resistance of falciparum malaria to the world’s most effective antimalarial drug, artemisinin, was widespread in Southeast Asia. Health experts fear that artemisinin resistant parasites will spread from their original Cambodian-Thai border epicentre in Southeast Asia and emerge on the Indian subcontinent and then sub-Saharan Africa, putting millions of lives at risk.

Coordinated by the Mahidol Oxford Tropical Medicine Research Unit (MORU) the TRACII study investigates the efficacy, safety and tolerability of triple artemisinin combination therapies (TACTs), which consist of a rapidly acting artemisinin derivative in combination with two slowly eliminated antimalarial partner drugs.

“Falciparum malaria is becoming almost untreatable in the region and new antimalarials are years away. TACTs combining existing antimalarial drugs may prove to be our most important remaining treatment option,” said Prof. Arjen Dondorp, Head of Malaria at MORU and principal investigator of TRACII, at the meeting.

Artemisinin resistance selects for resistance toward the partner drug, causing alarmingly low cure rates with artemisinin-based combination therapies (ACTs) in several countries of the Greater Mekong Sub-region. Deploying TACTs, which combine three drugs rather than two drugs as in conventional ACTs, might be an important treatment solution. 

“The TACTs that are currently assessed in TRACII are a combination of DHA-piperaquine plus mefloquine in Cambodia, Vietnam, Thailand and Myanmar and a combination of artemether-lumefantrine plus amodiaquine in Laos, Myanmar, Bangladesh, India and the Democratic Republic of the Congo. In total the TRACII project will enrol 2,040 subjects in 17 study sites in these eight countries,” said Dr Rob van der Pluijm, TRACII project coordinator.

In addition to discussions on the core study, TRAC II collaborators from the London School of Hygiene and Tropical Medicine (LSHTM), Institut Pasteur and the Armed Forces Research Institute of Medical Science (AFRIMS) presented preliminary results and future plans for their own TRACII related projects at the annual meeting.

“The TRAC studies are possible thanks to contributions from many regional and international partners,” said Dr Mehul Dhorda, head of the Asia Regional Centre & EQA Programme, WorldWide Antimalarial Resistance Network (WWARN). “The harmonised protocols and procedures being used for these studies will allow us to track resistance and directly compare data generated over time in disparate locations across the Greater Mekong Subregion.”

TRACII is funded by the United Kingdom Department for International Development (DFID).

Similar stories

New SMRU building opened in Thailand to provide health care to marginalized populations

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.

Constant genetic surveillance necessary to keep multidrug-resistant malaria parasite strains in check, study finds

Continually monitoring malaria parasite populations is necessary to prevent outbreaks of previously dormant multidrug-resistant malaria strains, say University of Oxford researchers. Multidrug-resistant malaria parasite strains can rapidly grow or collapse in response to public health policy changes, say the researchers in a study published today in The Lancet.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Combating drug-resistant malaria

MORU research has contributed to strategies to eliminate malaria in the Greater Mekong Sub-region, helping to prevent the spread of drug-resistant malaria and improving health provision and outcomes for remote communities.

Study shows clear link between antibiotic treatment and acquisition of AMR bacteria in children

A study of the genetic diversity of Streptococcus pneumoniae, the bacterium responsible for hundreds of thousands of infant deaths each year, found that deep sequencing whole pneumococcal populations gave unsurpassed sensitivity for detecting multiple colonisations and was twice as effective at detecting invasive virulent strains of the bacteria as current best methods, say researchers in a study published in Nature Microbiology.

Antimalarial chemoprophylaxis for forest goers could help accelerate malaria elimination in Cambodia

Giving people antimalarials during and after visiting the forest reduced their risk of contracting malaria 6-fold, and could be the missing piece towards eliminating malaria in Asia-Pacific and South America, say Mahidol and Oxford University researchers in a study published in The Lancet Infectious Diseases.